Cardiome Pharma (CRME) announced that the European Medicines Agency's (EMA) has approved the  dosing regimen of a single 30-minute 1500 mg infusion (three 500 mg vials) for its antibiotic XYDALBA (dalbavancin). The original approved dose was 1000 mg (two 500 mg vials) followed a week later by 500 mg (one vial). The approval aligns the label with the U.S. where the product is branded as DALVANCE. The FDA approved the regimen in January.